On the other hand, cancer may exploit this mechanism to evade NK cell mediated immune surveillance by upregulation of HLA-E9–13,40, leading to preferential expansion of NKG2A+ NK cells and thus depletion of potentially more responsive, uninhibited NK cells lacking NKG2A. Here, KLRC1 is linked to cancer.